Skip to main content
. 2022 Oct 20;15:2245–2252. doi: 10.2147/CCID.S387759

Figure 1.

Figure 1

Drug survival rate for four biological agents. The overall drug survival rate of guselkumab, ixekizumab, secukinumab and adalimumab was 72.2%, 67.1%, 63.0%, and 37.1%, respectively.